445
Participants
Start Date
December 16, 2020
Primary Completion Date
February 28, 2023
Study Completion Date
February 28, 2027
Percutaneous Coronary Intervention
Percutaneous coronary intervention of de novo native coronary artery lesions
AZ Middelheim Hospital, Antwerp
AZ Sint Jan Brugge, Bruges
Ziekenhuis Oost-Limburg, Genk
Universitaire Ziekenhuizen Leuven, Leuven
Kerkhoff Klinik GmbH, Bad Nauheim
Segeberger Kliniken GmbH, Bad Segeberg
REGIOMED Klinikum Coburg, Coburg
St. Johannes Hospital, Dortmund
Universitatsklinikum Erlangen, Erlangen
Elisabeth Krankenhaus Essen, Essen
MVZ CCB Frankfurt, Frankfurt
Universitatsklinikun Giessen, Giessen
Universitätsklinikum Jena, Jena
UKSH Kiel Klinik, Kiel
Universitätsmedizin-Mainz, Mainz
Krankenhaus der barmherzigen Bruder, Trier
Kokura Memorial Hospital, Kitakyushu
Shinkoga Hospital, Kurume
Sapporo Higashi Tokushukai Hospital, Sapporo
Takahashi Hospital, Tsuchiura
Tsuchiura Kyodo Hospital, Tsuchiura
Tenyokai Central Hospital, Kagoshima
Shonan Kamakura General Hospital, Kamakura
Kanto Rosai Hospital, Kawasaki-shi
Yokohama City Eastern Hospital, Yokohama
Kumamoto Rousai Hospital, Kumamoto
Miyazaki Medical Association Hospital, Miyazaki
Oumi Hachiman City General Medical Center, Hachiman
Cardiovascular Reaearch Institute, Tokyo
Teikyo University Hospital, Tokyo
Auckland City Hospital, Auckland
Middlemore Clinical Trials Trust, Auckland
Waikato Hospital, Auckland
Christchurch Hospital, Christchurch
Dunedin Hospital, Dunedin
North Shore Hospital, Takapuna
Lead Sponsor
Elixir Medical Corporation
INDUSTRY